Thijs de Rooij
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thijs de Rooij has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Marc Gerard Besselink
Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
9 shared publications Marcel Dijkgraaf
5 shared publications- Olivier Rc Busch
Department of Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands
5 shared publications Olivier Busch
4 shared publications- Djamila Boerma
Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands
3 shared publications - Erwin van der Harst
Department of Surgery, Maasstad Hospital, 3079 DZ Rotterdam, The Netherlands
3 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S6-S7
Laparoscopic versus open pancreatoduodenectomy (LEOPARD-2): A multicenter patient-blinded, randomized controlled trial
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S6-S7
Laparoscopic versus open pancreatoduodenectomy (LEOPARD-2): A multicenter patient-blinded, randomized controlled trial
- Top Cited PapersOpen Access
- 3 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-10
Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial
Data from observational studies suggest that minimally invasive pancreatoduodenectomy (MIPD) is superior to open pancreatoduodenectomy regarding intraoperative blood loss, postoperative morbidity, and length of hospital stay, without increasing total costs. However, several case-matched studies failed to demonstrate superiority of MIPD, and large registry studies from the USA even suggested increased mortality for MIPDs performed in low-volume (<10 MIPDs annually) centers. Randomized controlled multicenter trials are lacking but clearly required. We hypothesize that time to functional recovery is shorter after MIPD compared with open pancreatoduodenectomy, even in an enhanced recovery setting. LEOPARD-2 is a randomized controlled, parallel-group, patient-blinded, multicenter, phase 2/3, superiority trial in centers that completed the Dutch Pancreatic Cancer Group LAELAPS-2 training program for laparoscopic pancreatoduodenectomy or LAELAPS-3 training program for robot-assisted pancreatoduodenectomy and have performed ≥ 20 MIPDs. A total of 136 patients with symptomatic benign, premalignant, or malignant disease will be randomly assigned to undergo minimally invasive or open pancreatoduodenectomy in an enhanced recovery setting. After the first 40 patients (phase 2), the data safety monitoring board will assess safety outcomes (not blinded for treatment allocation) and decide on continuation to phase 3. Patients from phase 2 will then be included in phase 3. The primary outcome measure is time (days) to functional recovery. All patients will be blinded for the surgical approach, at least until postoperative day 5, but preferably until functional recovery has been attained. Secondary outcome measures are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life, and costs. The LEOPARD-2 trial is designed to assess whether MIPD reduces time to functional recovery, as compared with open pancreatoduodenectomy in an enhanced recovery setting. Netherlands Trial Register, NTR5689 . Registered on 2 March 2016.
- 3 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-10
Top Cited PapersOpen AccessMinimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial
Data from observational studies suggest that minimally invasive pancreatoduodenectomy (MIPD) is superior to open pancreatoduodenectomy regarding intraoperative blood loss, postoperative morbidity, and length of hospital stay, without increasing total costs. However, several case-matched studies failed to demonstrate superiority of MIPD, and large registry studies from the USA even suggested increased mortality for MIPDs performed in low-volume (<10 MIPDs annually) centers. Randomized controlled multicenter trials are lacking but clearly required. We hypothesize that time to functional recovery is shorter after MIPD compared with open pancreatoduodenectomy, even in an enhanced recovery setting. LEOPARD-2 is a randomized controlled, parallel-group, patient-blinded, multicenter, phase 2/3, superiority trial in centers that completed the Dutch Pancreatic Cancer Group LAELAPS-2 training program for laparoscopic pancreatoduodenectomy or LAELAPS-3 training program for robot-assisted pancreatoduodenectomy and have performed ≥ 20 MIPDs. A total of 136 patients with symptomatic benign, premalignant, or malignant disease will be randomly assigned to undergo minimally invasive or open pancreatoduodenectomy in an enhanced recovery setting. After the first 40 patients (phase 2), the data safety monitoring board will assess safety outcomes (not blinded for treatment allocation) and decide on continuation to phase 3. Patients from phase 2 will then be included in phase 3. The primary outcome measure is time (days) to functional recovery. All patients will be blinded for the surgical approach, at least until postoperative day 5, but preferably until functional recovery has been attained. Secondary outcome measures are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life, and costs. The LEOPARD-2 trial is designed to assess whether MIPD reduces time to functional recovery, as compared with open pancreatoduodenectomy in an enhanced recovery setting. Netherlands Trial Register, NTR5689 . Registered on 2 March 2016.
- Open Access
- 8 April 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-10
Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial
Observational cohort studies have suggested that minimally invasive distal pancreatectomy (MIDP) is associated with better short-term outcomes compared with open distal pancreatectomy (ODP), such as less intraoperative blood loss, lower morbidity, shorter length of hospital stay, and reduced total costs. Confounding by indication has probably influenced these findings, given that case-matched studies failed to confirm the superiority of MIDP. This accentuates the need for multicenter randomized controlled trials, which are currently lacking. We hypothesize that time to functional recovery is shorter after MIDP compared with ODP even in an enhanced recovery setting. LEOPARD is a randomized controlled, parallel-group, patient-blinded, multicenter, superiority trial in all 17 centers of the Dutch Pancreatic Cancer Group. A total of 102 patients with symptomatic benign, premalignant or malignant disease will be randomly allocated to undergo MIDP or ODP in an enhanced recovery setting. The primary outcome is time (days) to functional recovery, defined as all of the following: independently mobile at the preoperative level, sufficient pain control with oral medication alone, ability to maintain sufficient (i.e. >50%) daily required caloric intake, no intravenous fluid administration and no signs of infection. Secondary outcomes are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life and costs. The LEOPARD trial is designed to investigate whether MIDP reduces the time to functional recovery compared with ODP in an enhanced recovery setting. Dutch Trial Register, NTR5188 . Registered on 9 April 2015
- 8 April 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 1-10
Open AccessMinimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial
Observational cohort studies have suggested that minimally invasive distal pancreatectomy (MIDP) is associated with better short-term outcomes compared with open distal pancreatectomy (ODP), such as less intraoperative blood loss, lower morbidity, shorter length of hospital stay, and reduced total costs. Confounding by indication has probably influenced these findings, given that case-matched studies failed to confirm the superiority of MIDP. This accentuates the need for multicenter randomized controlled trials, which are currently lacking. We hypothesize that time to functional recovery is shorter after MIDP compared with ODP even in an enhanced recovery setting. LEOPARD is a randomized controlled, parallel-group, patient-blinded, multicenter, superiority trial in all 17 centers of the Dutch Pancreatic Cancer Group. A total of 102 patients with symptomatic benign, premalignant or malignant disease will be randomly allocated to undergo MIDP or ODP in an enhanced recovery setting. The primary outcome is time (days) to functional recovery, defined as all of the following: independently mobile at the preoperative level, sufficient pain control with oral medication alone, ability to maintain sufficient (i.e. >50%) daily required caloric intake, no intravenous fluid administration and no signs of infection. Secondary outcomes are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life and costs. The LEOPARD trial is designed to investigate whether MIDP reduces the time to functional recovery compared with ODP in an enhanced recovery setting. Dutch Trial Register, NTR5188 . Registered on 9 April 2015
- 1 June 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (3) , S38
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer
- 1 June 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (3) , S38
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15738
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer.
E15738 Background: FOLFIRINOX and irreversible electroporation(IRE) show promising results for locally advanced pancreatic cancer(LAPC). However, most studies only include patients with stable disease under chemotherapy. Our aim was to describe outcomes of multimodality treatment with FOLFIRINOX-chemotherapy, surgical exploration and IRE in a complete LAPC-cohort. Methods: Prospective single-center cohort (09.2013-03.2015), including all consecutive histologically proven LAPC-patients ( > 90°arterial or > 270°venous involvement). Preferred chemotherapy consisted of FOLFIRINOX, or, if unfeasible, gemcitabine. Radiotherapy was only used for local pain control. After three months, restaging was performed to assess RECIST1.1-response, radiological resectability and IRE-eligibility (tumor ≤ 5cm). All patients with non-progressive disease (RECIST) and IRE-eligible tumors underwent explorative laparotomy. Results: Of 132 patients with LAPC, 70% (n = 93) received chemotherapy (63% (n = 59) FOLFIRINOX). After 3 months, 45% (n = 59/132) had non-progressive disease. Of all 132 patients, 27% (n = 36) underwent surgical exploration with a resection in 11% (n = 14/132, R0 8/14) and IRE in 11% (n = 15/132). After surgical exploration, the Clavien-Dindo grade ≥ 3 complication rate was 39% (6/14 resection, 7/15 IRE, 1/7 other) and 90-day mortality 11% (1/14 resection, 2/15 IRE, 1/7 other). Median overall survival (mOS) and 1-year cumulative survival from diagnosis were 11 months and 43% respectively for all patients, 19 months and 71% for patients with non-progressive disease, 23 months and 82% in resected patients, and 16 months and 71% in IRE patients, with a median follow up of 10 months. Conclusions: A multimodality approach to LAPC is feasible with acceptable outcomes, especially in patients receiving FOLFIRINOX. This study highlights the importance of reporting on the outcomes of consecutive rather than selected cohorts of LAPC. Final survival data will have to be awaited before the added value of IRE can be evaluated. Clinical trial information: NTR4230.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e15738
Multimodality treatment of 132 consecutive patients with locally advanced pancreatic cancer.
E15738 Background: FOLFIRINOX and irreversible electroporation(IRE) show promising results for locally advanced pancreatic cancer(LAPC). However, most studies only include patients with stable disease under chemotherapy. Our aim was to describe outcomes of multimodality treatment with FOLFIRINOX-chemotherapy, surgical exploration and IRE in a complete LAPC-cohort. Methods: Prospective single-center cohort (09.2013-03.2015), including all consecutive histologically proven LAPC-patients ( > 90°arterial or > 270°venous involvement). Preferred chemotherapy consisted of FOLFIRINOX, or, if unfeasible, gemcitabine. Radiotherapy was only used for local pain control. After three months, restaging was performed to assess RECIST1.1-response, radiological resectability and IRE-eligibility (tumor ≤ 5cm). All patients with non-progressive disease (RECIST) and IRE-eligible tumors underwent explorative laparotomy. Results: Of 132 patients with LAPC, 70% (n = 93) received chemotherapy (63% (n = 59) FOLFIRINOX). After 3 months, 45% (n = 59/132) had non-progressive disease. Of all 132 patients, 27% (n = 36) underwent surgical exploration with a resection in 11% (n = 14/132, R0 8/14) and IRE in 11% (n = 15/132). After surgical exploration, the Clavien-Dindo grade ≥ 3 complication rate was 39% (6/14 resection, 7/15 IRE, 1/7 other) and 90-day mortality 11% (1/14 resection, 2/15 IRE, 1/7 other). Median overall survival (mOS) and 1-year cumulative survival from diagnosis were 11 months and 43% respectively for all patients, 19 months and 71% for patients with non-progressive disease, 23 months and 82% in resected patients, and 16 months and 71% in IRE patients, with a median follow up of 10 months. Conclusions: A multimodality approach to LAPC is feasible with acceptable outcomes, especially in patients receiving FOLFIRINOX. This study highlights the importance of reporting on the outcomes of consecutive rather than selected cohorts of LAPC. Final survival data will have to be awaited before the added value of IRE can be evaluated. Clinical trial information: NTR4230.
- 1 June 2015
- Published by Elsevier in Pancreatology
- Vol. 15 (3) , S109
Nationwide study on survival after distal pancreatectomy for pancreatic ductal adenocarcinoma
- 1 June 2015
- Published by Elsevier in Pancreatology
- Vol. 15 (3) , S109
Nationwide study on survival after distal pancreatectomy for pancreatic ductal adenocarcinoma
- Open Access
- 26 March 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 119
Electromagnetic guided bedside or endoscopic placement of nasoenteral feeding tubes in surgical patients (CORE trial): study protocol for a randomized controlled trial
- 26 March 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 119
Open AccessElectromagnetic guided bedside or endoscopic placement of nasoenteral feeding tubes in surgical patients (CORE trial): study protocol for a randomized controlled trial
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S9-S10
Laparoscopic versus open distal pancreatectomy for benign and malignant disease: A multicenter retrospective analysis
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S9-S10
Laparoscopic versus open distal pancreatectomy for benign and malignant disease: A multicenter retrospective analysis